Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats

Journal of Physiology and Pharmacology

Volumn 54, Issue 2, 2003, Pages 271-281

  Braszko, J J ^a   Kulakowska A ^a   Winnicka, M M ^a  

^a NONE

Author keywords

Angiotensin II; Anxiety; Losartan; Memory; Motor activity; PD 123319

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; LOSARTAN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; MAZE TEST; MOTOR ACTIVITY; NEUROMODULATION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; RECEPTOR BLOCKING;

EID: 0038127149     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Mosimann R, Imboden H, Felix D. The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory. Biol Rev Camb Philos Soc 1996; 71: 545-559.
2. 2 angiotensin receptors to its cognitive effects. Acta Neurobiol Exp 1996; 56: 49-54.
3. Wright JW, and Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994; 18: 21-53.
4. Hein L, Barsh GS, Pratt RE, Dzau V, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995; 377: 744-747.
5. Albrecht D, Nitschke T, von Bohlen und Halbach O. Various effects of angiotensin II on amygdaloid neuronal activity in normotensive control and hypertensive transgenic [TGR(mREN-2)27] rats. FASEB J 2000; 14: 925-931.
6. 1 receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. Behav Brain Res 2002; 131: 79-86.
7. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: functional implications. Front Neuroendocrinol 1995; 16: 23-52.
8. Wayner MJ, Armstrong DL, Phelix CF, Wright JW, Harding JW. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001; 22: 1403-1414.
9. Kułakowska A, Karwowska W, Wiśniewski K, Braszko JJ. Losartan influences behavioural effects of angiotensin II in rats. Pharmacol Res 1996; 34: 109-115.
10. Delorenzi A, Maldonaldo H. Memory enhancement by the angiotensinergic system in the crab Chasmagnathus is mediated by endogenous angiotensin II. Neurosci Lett 1999; 266: 1-4.
11. Morgan JM, Routtenberg A. Angiotensin injected into the neostriatum after learning disrupts retention performance. Science 1977; 196: 87-89.
12. 1 receptor. Peptides 1995; 16(6): 1069-1071.
13. Walther T, Voigt JP, Fukamizu A, Fink H, Bader M. Learning and anxiety in angiotensin-deficient mice. Behav Brain Res 1999; 100: 1-4.
14. Baranowska D, Braszko JJ, Wiśniewski K. Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats. Psychopharmacology 1983; 81: 247-251.
15. Wiśniewski K, Braszko JJ. The significance of central monoamine systems in the angiotensin II (AII) improvement of learning. Clin Exp Hypertension 1984; 6: 2127-2131.
16. Braszko JJ, Własienko J, Koziołkiewicz W, Janecka A, Wiśniewski K. The 3-7 fragment of angiotensin II is probably responsible for its psychoactive properties. Brain Res 1991; 542: 49-54.
17. Braszko JJ, Kupryszewski G, Witczuk B, Wigniewski K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and conditioned avoidance responses in rats. Neuroscience 1988; 27: 777-783.
18. Kaiser FC, Palmer GC, Wallace AV, Carr RD, Fraser-Rae L, Hallam C. Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. Neuro Report 1992; 3: 922-924.
19. Galani R, Duconseille E, Bildstein O, Cassel J.C. Effects of room and cage familiarity on locomotor activity measures in rats. Physiol Behav 2001; 74: 1-4.
20. Robbins T, Iversen S. A dissociation of the effects of d-amphetamine on locomotor activity and exploration in rats. Psychopharmacologia (Berl.) 1973; 28: 155-164.
21. Tachibana T. Mapping of open-field behavior in rats and integration of various independent study results. Physiol Behav 1985; 34: 83-87.
22. Wilkie DM, Willson RJ, Carr JAR. Errors made by animals in memory paradigms are not always due to failure of memory. Neurosci Biobehav Rev 1999; 23: 451-455.
23. Walters DE, Speth RC. Neuronal localization of specific angiotensin II binding sites in the rat inferior olivary nucleus. J Neurochem 1988; 50: 812-817.
24. 2 receptors in the cerebellar cortex of young rats. Brain Res 1998; 793: 176-186.
25. Barnes JM, Barber PC, Barnes NM. Identification of angiotensin II receptor subtypes in human brain. NeuroReport 1991; 2: 605-608.
26. Marin J, Govantes C. Angiotensin-converting enzyme inhibitors and the role of nitric oxide and excitatory amino acids in improvement of cognition and memory. J Auton Pharmacol 1995; 15: 129-149.
27. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BLM, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-750.
28. Sakagawa T, Okuyama S, Kawashima N, Hozumi S, Nakagawasai O, Tadano T, Kisara K, Ichiki T, Inagami T. Pain threshold, learning and formation of brain edema in mice lacking the angiotensin II type 2 receptor. Life Sci 2000; 67: 2577-2585.
29. Okuyama S, Sakagawa T, Inagami T. Role of the angiotensin II type-2 receptor in the mouse central nervous system. Jpn J Pharmacol 1999; 81: 259-263.
30. Wilson W, Voight P, Bader M, Marsden CA, Fink H. Behaviour of the transgenic (mREN2) 27 rat. Brain Res 1996; 729: 1-9.
31. 2) in rat brain. Am J Physiol 1991; 261: R209-R216.
32. Nutt DJ, Glue P. Clinical pharmacology of anxiolytics and antidepressant: a psychopharmacological perspective. In Psychopharmacology of Anxiolytics and Antidepressants, SE File (ed.). New York, Pergamon Press, Inc, 1991, pp. 1-28.
33. Davis M. Animal models of anxiety based on clinical conditioning: the conditioned emotional response and the fear-potentiated startle effect. In Psychopharmacology of Anxiolytics and Antidepressants, SE File (ed.). New York, Pergamon Press, Inc, 1991, pp. 187-212.
34. Peng JF, Phillips MI. Opposite regulation of brain angiotensin type 1 and type 2 receptors in cold-induced hypertension. Regul Peptides 2001; 97: 91-102.
35. 2 receptors. Endocrinology 1997; 138: 2195-2198.
36. Watanabe T, Hashimoto M, Okuyama S, Inagami T, Nakamura S. Effects of targeted disruption of mouse angiotensin II type 2 receptor gene on stress-induced hypertermia. J Physiol (Lond) 1999; 515: 881-885.
37. Braszko JJ, Wiśniewski K, Kupryszewski G, Witczuk B. Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs cognitive behaviour. Behav Brain Res 1987; 25: 195-203.
38. Pellow S, Chopin P, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167.
39. Graeff FG, Netto CF, Zangrossi Jr. H. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 1998; 23: 237-246.
40. Boissier PJR, Tardy J, Diverres JC. Une nouvelle méthode simple pour explorer l'action 'tranquillisante': le test de la cheminée. Med Exp 1960; 3: 81-84.
41. Czuczwar M, Kiś J, Potasiński A, Turski WA, Przesmycki K. Isobolographic analysis of interaction between vigabatrin and baclofen in the formalin test in mice. Pol J Pharmacol 2002; 53: 527-530.
42. Mondadori C. Avoidance conditioning: methods and problems. Pharmac Ther 1979; 5: 423-425.
43. Elrod K, Buccafusco JJ. Microinjection of vehicle into the nucleus basalis magnocellularis results in task - specific impairment of passive avoidance responding. Res Commun Psychol Psychiatr Behav 1988; 13: 271-284.
44. Ekestam N, Zhu S, Folkesson R, Winblad B, Ganten D, Mohhamed AH. Learning and emotional behavior in the hepertensive renin-2 transgenic rats. Behav Brain Res (in press).
45. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Human Hypertens 1997; 11: S45-S47.
46. Thürmann PA, Kenedi P, Schmidt A. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
47. Mueck AO, Seeger H, Lippert TH. Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. Int J Clin Pharmacol Ther 1999; 37: 365-366.
48. Ader R, Weijnen JAWM, Moleman P. Retention of a passive avoidance responses as a function of the intensity and duration of electric shock. Psychon Sci 1972; 26: 125-129.
49. Winnicka MM. Dopaminergic projection to the nucleus accumbens mediates the memory - enhancing effects of angiotensins in rats. Pharmacol Biochem Behav 1999; 62: 625-630.
50. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: functional implications. Front Neuroendocrinol 1995; 16: 23-52.
51. DeNoble VJ, DeNoble KF, Spencer KR, Chiu AT, Wong PC, Timmermans BMWM. Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a renin-induced deficit of a passive avoidance response in rats. Brain Res 1991; 561: 230-235.
52. Sahgal A. A critique of the vasopressin-memory hypothesis. Psychopharmacology 1984; 83: 215-228.